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Abstract 
Metabolism is the process carried out in the cells of all living organisms converting the food 
we eat to chemical energy needed for sustaining life. It encompasses allbiochemical processes 
that occur within any living organism - including humans - to maintain life. These 
biochemical processes allow us to grow, reproduce, repair damage, and respond to our 
environment. 
 
 
 
.
Introduction 
 
Inborn errors in metabolism 
Inborn errors of metabolism are rare genetic disorders in 
which the body cannot properly convert food into chemical 
energy or any other compound in various metabolic pathways 
so far investigated. The disorders are usually caused by 
defects in single or more genes as a result of which specific 
proteins or enzymes which are required to break down or 
metabolize compounds are not properly coded resulting in 
faulty secondary and tertiary structures. A food product that is 
not broken down properly to give energy or the next 
compound in metabolic pathways causes significant blockage 
in the metabolic pathway either by accumulating substrates 
behind the block or deficiency of the product, resulting in a 
wide array of symptoms. Several inborn errors of metabolism 
cause developmental delay if not controlled or rectified. 
A large number of inborn errors of metabolism have been 
discovered and elucidated.  All inborn metabolic errors are 
genetically transmitted typically in an autosomal recessive or 
X-linked recessive fashion. A few of them are highlighted in 
this chapter.  
 
Disorders of carbohydrate metabolism 
Galactosemia, an autosomal recessive inheritable metabolic 
disorder caused due to mutation in the GALT gene located on 
the short arm of chromosome 9 coding for the engyme 
(galactose-1- phosphate uridyl transferase) needed for the 
proper utilization of galactose into energy yielding pathways. 
Lactose is the major sugar present in milk and it is digested 
into glucose and galactose. Further galactose is digested and 
broken down to yield energy. In the absence of GALT 
engyme, galactose gets accumulated and elevates blood 
gulactose level, this build up of galactose causes cellular 
damage to the liver, eye and brain, and may even cause death  
to neonates.1 
Hereditary fructose intolerance, is an autosomal recessive 
disorder caused by mutation of the Aldo B gene located on 
chromosome 9q22.3.In the deficieny of Aldolase B engyme, 
its substrate, fructose-1-phosphate (F1P), accumulates in the 
liver and kidneys and has a variety of adverse effects. 
Aldolase B is the only enzyme that breaks down F1P and 
facilitates its entry into the Kreb’s cycle. In the absence of 
fructose breakdown aldolase B engyme, fructose 1-phosphate 
is  unabsorbed. Fructose osmotically reduces the absorption of 
water which accumulates in the gut where its breakdown by 
the normal colonic bacteria (in the gut) to short chain fatty 
acids and release of the gases hydrogen, carbon dioxide and 
methane ensues. The abnormal increase in hydrogen can be 
detected with the hydrogen breath test, one of the techniques 
employed to assess patients with suspected fructose 
malabsorption. Symptoms of malabsorption include, bloating, 
diarrhoea or constipation, flatulence, and stomach pain due to 
muscle spasms and many more. 2,3,4 
Fructose 1,6-diphosphatase deficiency(FDP-ase), is an 
autosomal recessive disorder of gluconeogenesis. It converts 
fructose 1,6 -diphosphate (FDP) to fructose 6-phosphate (F-6-
P), which permits endogenous glucose production from 
gluconeogenic amino acids (eg, alanine and glycine), glycerol, 
or lactate.  Lack of FDPase accumulates intrahepatocellular 
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FDP, which inhibits gluconeogenesis and, if intracellular 
phosphate stores are depleted, inhibits glycogenolysis. The 
inability to convert lactic acid or glycerol into glucose leads 
to hypoglycaemia, lactic acidosis, and glyceroluria. 5 
Glycogen storage diseases (GSDs) is another inheritable 
genetic disorder where storage of excessive glycogen due to 
lack of specific enzyme which breaks down glycogen to 
glucose. Glycogen is mainly stored in muscles and liver and  
when excess storage of glycogen in muscles and in liver 
remain unmetabolized, it  leads to various disease types 
summarized below:- 
The main types of GSDs  categorized by number and name 
and include:  
Type I- (Von Gierke disease, defect in glucose-6-
phosphatase)—most common type of GSD; accounts for 90% 
of all GSD cases. 
 
Type II- (Pompe’s disease, acid maltase deficiency). 
 
Type III- (Cori’s disease, debrancher enzyme deficiency). 
 
Type IV- (Andersen’s disease, brancher enzyme deficiency). 
 
Type V- (McArdle’s disease, muscle glycogen phosphorylase 
deficiency). 
 
Type VI- (Hers’ disease, liver phosphorylase deficiency). 
 
Type VII- (Tarui’s disease, muscle phosphofructokinase 
deficiency). 
 
Type IX- (liver glycogen phosphorylase kinase deficiency). 6 
 
 
Disorders of amino acid metabolism  
Phenylketonuria, is an autosomal recessive genetic disorder 
causing inborn error in amino acid metabolism. This defect 
occurs due to deficiency in production of hepatic enzyme 
phenylalanine hydroxy-lase encoded by PHA gene. This 
enzyme converts phenylalanine to tyrosine. Tyrosine is 
another amino acid and is one of the main constituents of 
protein synthesis and further helps in building up the body. In 
the absence of the enzyme phenylalanine hydroxy-lase, 
phenylalanine gets accumulated and interferes with brain 
development and also causes deficiency of tyrosine. The 
excess of phenylalanine get converted to phenylketone, a bad 
smelling compound for which the disease is named. This 
defect resuls in mental disorders and in neuropsychological 
dysfunctioning 7 
 
Hereditary tyrosinemia  
These are of three types, type 1 Tyrosinemia( also known as 
Hereditary Infantile Tyrosinemia and Hepatorenal 
Tyrosinemia), type 2 Tyrosinemia (Oculocutaneous 
tyrosinemia) and type 3 Tyrosinemia. 
 
Type 1 Tyrosinemia is a genetic metabolic disorder caused 
due to lack of the enzyme fumaryl lacetoacetate hydrolase 
(FAH) and p-hydroxyphenylpyruvate hydroxylase. FAH 
enzyme is needed in the breakdown of the amino acid 
tyrosine. In the absence of the above enzyme tyrosine gets 
abnormally accumulated in the liver and results in the liver 
dysfunctioning. Tyrosine also gets accumulated in the kidney 
and in central nervous system. 
 
Type 2 Tyrosinemia disorders are inherited autosomal 
recessive characters, an enzyme defect in hepatic tyrosine 
amino transferase (TAT) encoded by the gene TAT. This 
enzyme is one of the enzymes needed for the digestion of 
tyrosine. 8 
 
Type 3 tyrosinemia is an inheritable autosomal recessive 
disorder  caused by the deficiency of the enzyme 4-
hydroxyphenylpyruvate dioxygenase (4-HPPD) encoded by 
HPD gene, an enzyme involved in the catabolic pathway of 
tyrosine.  Enzyme deficiency  disorder is characterized by 
elevated levels of blood tyrosine and massive excretion of 
tyrosine derivatives into urine 9,10 
 
Maple syrup urine disease [MSUD]:  is the  inability to 
metabolise the three branched chain amino acids, leucine, 
isoleucine and valine. The breakdown products of these amino 
acids, alpha- keto acids, accumulate and are eliminated 
through urine. The urine consequently  has the odour of maple 
syrup or burned caramel. This disorder is non-treatable, the 
infant becomes severely acidotic and may prove fatal.   
 
Nonketotic hyperglycinemia (NKH): is a rare genetic 
inherited autosomal recessive disorder. This disease is 
characterized by elevated concentration of glycerine in the 
body fluids due to molecular disorder in the glycine cleavage 
enzyme system (GCS). The glycine cleavage enzyme system 
comprises of four proteins P-, T-, H- and L-proteins, and 
mutations have been described in the GLDC, AMT and GCSH 
genes encoding the P-, T-, and H-proteins respectively.11,12 
 
Homocystinuria  
Cystathionine beta synthase deficiency or CBS deficiency. 
Inherited autosomal recessive trait, amino acid methionine 
metabolism disorder and also known as multisystemic clinical 
disorder. Mutations in the CBS gene cause the most common 
form of homocystinuria. The CBS gene encodes for 
production of an enzyme called cystathionine beta-synthase. 
This disease results in the elevated plasma and urine 
homocysteine and methionine levels and decreased levels of 
cystathionine and cysteine because of deficient activity of 
cystathionine beta synthetase, the enzyme catalyzing 
conversion of homocysteine to cystathionine.13,14 
 
Urea Cycle Disorder or Urea Cycle Defects:  
 Citrullinemia, is an autosomal recessive urea disorder. It is 
of two types due to defects in two genes at  different locations 
on chromosomes. Citrullinemia type I (CTLNI) and 
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Citrullinemia type II (CTLN2), mutations have been reported 
in the genes ASS and SLC25A13 respectively.15 
Citrullinemia type I (CTLNI) disorder is a result of improper 
activity of enzyme arginino-succinate synthetase (ASS) which 
plays an important role in the urea cycle and in the processing 
of nitrogen metabolism.  Due to mutation in gene ASS the 
above activities are not performed well and results in 
disruption in the digestion of nitrogen and this lead to excess 
accumulation of nitrogen in the form of ammonia and other 
by-products of the urea cycle in the blood and cause  type I 
citrullinemia.16 
 
Citrullinemia type II (CTLN2), is an autosomal recessive 
disorder caused by a mutation in the SLC25A13 gene, which 
inhibits the production of enzymeArginino-succinic acid 
synthetase. Mutation in the above gene results in improper 
urea cycle and hyperammonemia and elevates citrillin which 
disrupts the production of proteins and nucleotides.17 
 
Ornithine transcarbamylase (OTC) deficiency is an X-
linked inherited mitochondrial enzyme (mainly in the 
mitochondrial matrix of liver cells) that catalyze the synthesis 
of citrulline from carbamoyl phosphate and ornithine in the 
urea cycle. Mutation in the OTC gene located at Xp21.1  leads 
to a single base change (CCG to ACG) in exon 7, leading to 
the substitution of the amino acid threonine for a proline at 
position 225. Deficiency in the OTC production leads to 
hyperammonemic state which is toxic and lethal.18,19  And 
otherUrea Cycle Disorders are (c) arginosuccinic aciduria, (d) 
Carbamoyl phosphate synthetase I deficiency (e) Argininemia 
and (f) NAGS deficiency. 
 
Disorders of organic acid metabolism (organic acidurias): 
Alcaptonuria (black urine disease ) is a rare inherited genetic 
disorder of phenylalanine and tyrosine metabolism. This is an 
autosomal recessive trait the defects of which have been 
mapped on chromosome 3, between regions 3q21-q23.This 
disorder results due to a defect in the enzyme homogentisate 
1,2-dioxygenase (HGD), which participates in the degradation 
of tyrosine. The HGD enzyme catalyses the conversion of 
homogentisic acid (HGA) into 4-maleylacetoacetic acid but 
due to defect in the gene the enzyme HGD is not encoded as a 
result, homogentisic acid and its oxide, called alkapton, 
accumulate in the blood and are excreted in urine in large 
amounts.20 
 
Disorders of fatty acid oxidation 
Medium-chain acyl-coenzyme: A dehydrogenase 
deficiency (often shortened to MCADD) is an autsomal 
recessive disorder of Beta-oxidation of fatty acid also known 
as Beta-oxidation defects, are a distinct type of organic acid 
disorder. Deficiency of MCAD prevents the body from 
converting certain fats to energy particularly during fasting. 
This defect occurs due to mutation in ACADM gene, this 
gene encodes for MCAD. This abnormality leads to 
hypoketotic hypoglycemia, hyperammonemia, and 
cardiomyopathy, and may present clinically with Reye’s 
syndrome. Medium-chain acyl-CoA dehydrogenase 
deficiency (MCADD) is among the most common of all 
inborn metabolic errors and plays significant role in SIDS 
(sudden infant death syndrome) cases.21, 22 
Disorders of steroid metabolism: Congenital adrenal 
hyperplasia (CAH) caused due to mutation in gene encoding 
for protein/enzyme Steroid 21-hydroxylase. This is an 
autosomal recessivegenetic disorder and the genes for CAH 
are located on the chromosome number 6.(Steroid hormones 
bind to specific intracellular receptors which upon 
dimerization interact with the DNA in the nucleus. As a result 
gene activity is modulated and hormone specific response 
occurs.). 23 
 
Disorders of mitochondrial function:  Kearns-Sayre 
syndromeis a multisystem disorder caused by rearrangements 
of mitochondrial genome including various deletions and / or 
duplications. Symptoms appear before the age of 20 
years. External ophthalmoplegia, pigmentary retinopathy, 
ragged-red fibers on muscle biopsy, progressive degeneration 
of cardiac conduction system, ataxia and brain abnormalities 
such as leukoencephalopathy. 24, 25, 26, 27 
 
Disorders of peroxisomal function: Peroxisomal Biogenesis 
Disorders (PBD) refers to the disorders in the Zellweger 
Spectrum and are lethal autosomal recessive diseases caused 
due to mutation in the PEX gene. PEX gene encodes for the 
proteins known as peroxins associated in the metabolic 
pathway of the peroxisome. Zellweger Spectrum includes 
PBD phenotypes which are three in number i.e, (a) Zellweger 
Syndrome (ZS), (b) Neonatal Adrenoleuko-dystrophy 
(NALD) and (c) Infantile Refsum Disease (IRD). There are 
also two single enzyme peroxisomal disorders: acyl-CoA 
oxidase deficiency and D-bifunctional protein deficiency and 
are closely related to PBDs. These are all rare, genetic, 
metabolic, terminal conditions affecting all major systems of 
the body. They may present with features similar to the 
lysosomal storage disorders. Common features of Zellweger 
syndrome include large fontanel, organomegaly, Down-like 
facies, seizures and chondrodysplasia punctata. 28, 29, 30,31 
 
Lysosomal Storage Disorders (LSDs):  Most of the LSDs are 
the results of the defective lysosomal acid hydrolysis of 
endogenous macromolecules and their consequent 
accumulation.LSDs are categorised asmucopolysaccharidoses 
(MPSs), sphingolipidoses, mucolipidoses, glycoproteinoses, 
oligosaccharidoses, and glycogen storage diseases. These 
diseases are the results of the mutation in a single gene and are 
inherited in an autosomal recessive manner, exceptions like 
Fabry disease and Hunter disease (also called MPSII), which 
are X-linked recessive diseases. Glycogen Storage Disease 
(Pompe disease) due to deficiency of protein alpha-1, 4-
glycosidase or acid maltase mutation in the gene located at 
17q23. Sphingolipidoses (Tay-Sachs) beta-hexosaminidase A 
(alpha chain) 15q23-q24,( Niemann-Pick A and B) 
Sphingomyelinase 11p15.1-p15.4, (Fabry) alpha-galactosidase 
A Xq22, Lipidoses (Wolman) Acid lipase 10q23.2-q23.3, 
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Glycoproteinoses (Fucosidosis) alpha-fucosidase 1p24 and 
many more have been identified in modern times due to 
defective gene functioning, mutations leading to faulty amino 
acid substitutions, deletions etc. 31 
 Doubtless more such disorders of metabolism will be 
discovered in future as our knowledge increases. 
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